FLUCONAZOL KABI 2 MG/ML SOLUCION PARA PERFUSION EFG Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fluconazol kabi 2 mg/ml solucion para perfusion efg

fresenius kabi espaÑa, s.a.u. - fluconazol - soluciÓn para perfusiÓn - 400 mg - fluconazol 20 mg - fluconazol

FLUCONAZOL AUROBINDO 200 mg CAPSULAS DURAS EFG Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fluconazol aurobindo 200 mg capsulas duras efg

laboratorios aurobindo, s.l.u. - fluconazol - cÁpsula dura - 200 mg - fluconazol 200 mg - fluconazol

FLUCONAZOL AUROBINDO 50 mg CAPSULAS DURAS EFG Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fluconazol aurobindo 50 mg capsulas duras efg

laboratorios aurobindo, s.l.u. - fluconazol - cÁpsula dura - 50 mg - fluconazol 50 mg - fluconazol

FLUCONAZOL AUROBINDO 100 mg CAPSULAS DURAS EFG Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fluconazol aurobindo 100 mg capsulas duras efg

laboratorios aurobindo, s.l.u. - fluconazol - cÁpsula dura - 100 mg - fluconazol 100 mg - fluconazol

FLUCONAZOL AUROBINDO 150 mg CAPSULAS DURAS EFG Španělsko - španělština - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fluconazol aurobindo 150 mg capsulas duras efg

laboratorios aurobindo, s.l.u. - fluconazol - cÁpsula dura - 150 mg - fluconazol 150 mg - fluconazol

Clopidogrel Acino Evropská unie - španělština - EMA (European Medicines Agency)

clopidogrel acino

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.